Fig. 1
![Fig. 1](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12885-018-4817-4/MediaObjects/12885_2018_4817_Fig1_HTML.png)
CAR T cell therapy. T lymphocytes from the patient or a suitable donor are isolated. Then T cells are activated with anti-human CD3/CD28 antibody-coated beads, anti-CD3 monoclonal antibodies, and/or artificial antigen-presenting cells(APCs). The first, second or third generation CARs are transducted to T cells via a viral or nonviral vector (i.e., eletroporation). Engineered CAR T cells are expanded and infused into the patient who received or not received lymphodepletion regimen